Off-label psychopharmacologic prescribing for children: History supports close clinical monitoring

Child and Adolescent Psychiatry and Mental Health

Volumn 2, Issue , 2008, Pages

  Zito, Julie M ^a   Derivan, Albert T ^b   Kratochvil, Christopher J ^c   Safer, Daniel J ^d   Fegert, Joerg M ^e   Greenhill, Laurence L ^f  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d DEPARTMENT OF PATHOLOGY   (United States)

^e UNIVERSITY HOSPITAL ULM   (Germany)

^f Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; AMPHETAMINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATOMOXETINE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORAMPHENICOL; CHLORDIAZEPOXIDE; DESMOPRESSIN; DIAZEPAM; FLUOXETINE; FLURAZEPAM; HALOPERIDOL; LAMOTRIGINE; LITHIUM DERIVATIVE; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PEMOLINE; PHENOBARBITAL; PLACEBO; PROMETHAZINE; PROPOFOL; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID;

ADJUVANT THERAPY; AGITATION; ALLERGIC DISEASE; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; BLINDNESS; BRADYCARDIA; CHILD CARE; CLINICAL TRIAL; COGNITIVE DEFECT; COMMON COLD; COUGHING; DEPRESSION; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; DYSTONIA; EMOTIONAL DISORDER; EPILEPSY; FEBRILE CONVULSION; GLOMERULUS FILTRATION; HEART BLOCK; HOSTILITY; HUMAN; HYPERKINESIA; HYPERTENSION; HYPONATREMIA; HYPOPLASIA; HYPOTENSION; INFECTION; IRRITABILITY; LIVER DYSFUNCTION; LIVER METABOLISM; LIVER TOXICITY; MENTAL DISEASE; METABOLIC ACIDOSIS; METABOLIC SYNDROME X; MUSCLE RIGIDITY; NEPHROTOXICITY; NOCTURNAL ENURESIS; OFF LABEL DRUG USE; OVARY POLYCYSTIC DISEASE; OXYGEN THERAPY; PANCREATITIS; PATIENT EDUCATION; PATIENT MONITORING; PEDIATRIC ANESTHESIA; POSTMARKETING SURVEILLANCE; PREMATURITY; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOSIS; RESPIRATION DEPRESSION; RETROLENTAL FIBROPLASIA; REVIEW; RISK ASSESSMENT; SEIZURE; SIDE EFFECT; STEVENS JOHNSON SYNDROME; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE ATTEMPT; THYROID DISEASE; TOOTH DISEASE; TREATMENT INDICATION; TREMOR; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

EID: 54049141314     PISSN: None     EISSN: 17532000     Source Type: Journal    
DOI: 10.1186/1753-2000-2-24     Document Type: Review

References (73)

1. Roberts R Rodriguez W Murphy D Crescenzi T Pediatric drug labeling JAMA 2003, 290:905-911. 10.1001/jama.290.7.905 12928467
2. Turner S Nunn AJ Choonara I Unlicensed drug use in children in the UK The International Journal of Pharmacy 2004 http://www.priory.com/pharmol/ uduiciuk.htm
3. Fost N Ethical issues in research and innovative therapy in children with mood disorders Biol Psychiatry 2001, 49:1015-1022. 10.1016/ S0006-3223(01)01181-7 11430843
4. Behrman RE Kliegman RM Jenson HB Nelson Textbook of Pediatrics Elsevier Science 17 2003
5. Brunton LL Lazo JS Parker KL Goodman & Gilman's The Pharmacological Basis of Therapeutics The McGraw-Hill Companies 11 2006
6. Green WH Child and Adolescent Clinical Psychopharmacology New York: Lippincott Williams & Wilkins 4 2007
7. Strom BL Pharmacoepidemiology New York: John Wiley and Sons, Ltd 3 2000
8. Kinsey VE Zacharias L Retrolental fibroplasia JAMA 1949, 139:572-579.
9. Patz A The role of oxygen in retrolental fibroplasia Pediatrics 1957, 19:504-523. 13408030
10. Weiss CF Glazko AJ Weston JK Chloramphenicol in the newborn infant N Engl J Med 1960, 262:787-794. 13843700
11. Mirakhur RK Induction characteristics of propofol in children: comparison with thiopentone Anaesthesia 1988, 43:593-598. 10.1111/ j.1365-2044.1988.tb06699.x 3261948
12. Strickland RA Murray MJ Fatal metabolic acidosis in a pediatric patient receiving an infusion of propofol in the intensive care unit: Is there a relationship? Crit Care Med 1995, 23:405-409. 10.1097/ 00003246-199502000-00029 7867366
13. Arduino MJ Bland LA McAllister SK Aguero SM Villarino ME McNeil MM et al. Microbial growth and endotoxin production in the intravenous anesthetic propofol Infect Control Hosp Epidemiol 1991, 12:535-539. 1940276
14. Okamoto MP Kawaguchi DL Amin AN Evaluation of propofol infusion syndrome in pediatric intensive care Am J Health-Syst Pharm 2003, 60:2007-2014. 14531250
15. Gonzalez-Martin G Caroca CM Paris E Adverse drug reactions (ADRs) in hospitalized pediatric patients. A prospective study Int J Clin Pharmacol Ther 1998, 36(10):530-533. 9799056
16. Witkop CJ Jr Wolf RO Hypoplasia and intrinsic staining of enamel following tetracycline therapy JAMA 1963, 185:1008-1011. 14045567
17. Glauser TA Behavioral and psychiatric adverse events associated with antiepileptic drugs commonly used in pediatric patients J Child Neurol 2004, 19(Suppl 1):S25-S38. 15526968
18. Farwell JR Lee YJ Hirtz DG Sulzbacher SI Ellenberg JH Nelson KB Phenobarbital for febrile seizures-effects on intelligence and on seizure recurrence N Engl J Med 1990, 322:364-369. 2242106
19. Vining EPG Mellits ED Dorsen MM Cataldo MF Quaskey SA Spielberg SP et al. Psychologic and behavioral effects of antiepileptic drugs in children: A double-blind comparison between phenobarbital and valproic acid Pediatrics 1987, 80:165-174. 3112727
20. Nordli DR Medical treatment of the child with epilepsy Current Pediatric Therapy Philadelphia: Saunders Burg FD, Ingelfinger RA, Polin RA, Gershon AA 2002:448
21. Camfield CS Chaplin S Doyle AB Shapiro SH Cummings C Camfield PR Side effects of phenobarbital in toddlers: Behavioral and cognitive aspects J Pediatr 1979, 95:361-365. 10.1016/S0022-3476(79)80507-7 381616
22. NICHD Frequency of medication usage in the pediatric population, detailed report Contract # GS-23F-8144H. Bethesda, MD 2006
23. FDA Public Health Advisory: Nonprescription Cough and Cold Medicine Use in Children 2008 http://www.fda.gov/cder/drug/advisory/ cough_cold_2008.htm
24. Kahn A Blum D Phenothiazines and Sudden Infant Death Syndrome Pediatrics 1982, 70:75-78. 7088637
25. Zito JM Safer DJ dosReis S Gardner JF Magder L Soeken K et al. Psychotropic practice patterns for youth: A 10-year perspective Arch Pediatr Adolesc Med 2003, 157:17-25. 12517190
26. Goodwin R Gould MS Blanco C Olfson M Prescription of psychotropic medications to youths in office-based practice Psychiatric Services 2001, 52:1081-1087. 10.1176/appi.ps.52.8.1081 11474055
27. Safer DJ Zito JM Gardner JF Pemoline hepatotoxicity and post-marketing surveillance J Am Acad Child Adolesc Psychiatry 2001, 40:622-629. 10.1097/00004583-200106000-00006 11392339
28. Willy ME Manda B Shatin D Drinkard CR Graham DJ A study of compliance with FDA recommendations for pemoline (Cylert®) J Am Acad Child Adolesc Psychiatry 2002, 41:785-790. 10.1097/00004583-200207000-00009 12108802
29. Etwel FA Rieder MJ Bend JR Koren G A surveillance method for the early identification of idiosyncratic adverse drug reactions Drug Safety 2008, 31:169-180. 18217792
30. Strom BL How the US drug safety system should be changed JAMA 2006, 295:2072-2075. 10.1001/jama.295.17.2072 16670415
31. Koro CE Fedder DO L'Italien GJ Weiss SS Magder LS Kreyenbuhl J et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: Population based nested case-control study BMJ 2002, 325:243-245. 117636 12153919 10.1136/ bmj.325.7358.243
32. Correll CU Antipsychotic use in children and adolescents: Minimizing adverse effects to maximize outcomes J Am Acad Child Adolesc Psychiatry 2008, 47:9-20. 18174821
33. Zito JM Safer DJ Gardner JF Soeken K Ryu J Anticonvulsant treatment for psychiatric and seizure indication among youths Psychiatr Serv 2006, 57;681-685. 10.1176/appi.ps.57.5.681 16675763
34. Dreifuss FE Santilli N Langer DH Sweeney KP Moline KA Menander KB Valproic acid hepatic fatalities: A retrospective review Neurology 1987, 37:379-385. 3102998
35. Bryant AE Dreifuss FE Valproic acid hepatic fatalities. III. U.S. experience since 1986 Neurology 1996, 46:465-469. 8614514
36. Klein DF The flawed basis for FDA post-marketing safety decisions: The example of antidepressants and children Neuropsychopharmacology 2006, 31:689-699. 10.1038/sj.npp.1300996 16395296
37. March J Silva S Petrycki S Curry J Wells K Fairbank J et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial JAMA 2004, 292:807-820. 10.1001/ jama.292.21.2578-c 15315995
38. Emslie GJ Rush AJ Weinberg WA A double-blind, randomized placebo-controlled trial of fluoxetine in children and adolescents with depression Arch Gen Psychiatry 1997, 54:1031-1037. 9366660
39. Teicher MH Glod C Cole JO Emergence of intense suicidal preoccupation during fluoxetine treatment Am J Psychiatry 1990, 147(2):207-210. 2301661
40. King RA Riddle MA Chappell PB Hardin MT Anderson GM Lombroso P et al. Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment J Am Acad Child Adolesc Psychiatry 1991, 30:179-186, 2016219
41. Zito JM Safer DJ The efficacy and safety of selective serotonin reuptake inhibitors for the treatment of depression in children and adolescents Pharmacovigilance John Wiley & Sons Mann R, Andrews EB 2007, 559-570.
42. Hammad T Relationship between psychotropic drugs and pediatric suicidality FDA 2004, 1-131. http://www.fda.gov/ohrms/dockets/ac/04/ briefing/2004-4065b1-10-TAB08-Hammads-Review.pdf Accessed June 2005
43. Brown E Medical Dictionary for Regulatory Activities (MedDRA) Pharmacovigilance West Sussex: John Wiley & Sons Ltd Mann RD, Andrews EB 2007, 167-183.
44. Pliszka SR Carlson CL Swanson JM ADHD with Comorbid Disorders New York: Guilford Press 1999
45. FDA FDA Advisory: Suicidality and Antiepileptic Drugs 2008 http://www.fda.gov/cder/drug/Infopage/antiepileptics/default.htm
46. Greenhill LL Vitiello B Abikoff H Levine J March JS Riddle MA et al. Improving the methods for evaluating the safety of psychotropic medications in children and adolescents Curr Ther Res Clin Exp 2001, 62:873-884. 10.1016/S0011-393X(01)80092-8
47. Safer DJ Zito JM dosReis SM Concomitant psychotropic medication for youths Am J Psychiatry 2003, 160:438-449. 10.1176/appi.ajp.160.3.438 12611822
48. Zito JM Safer DJ Sai D Gardner JF Thomas D Coombes P et al. Psychotropic medication patterns among youth in foster care Pediatrics 2008, 121:e157-e163. 10.1542/peds.2007-0212 18166534
49. Correll CU Carlson HE Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents J Am Acad Child Adolesc Psychiatry 2006, 45(7):771-791. 16832314
50. Glaeske G Janhsen K GEK-Arzneimittel-Report 2007 2007 http://media.gek.de/downloads/magazine/GEK-Arzneimittel-Report-2007.pdf
51. EMEA Public Status Report on the Implementation of the European Risk Management Strategy London 2007 168954 http://www.emea.europa.eu/pdfs/ human/phv/16895407en.pdf
52. Riederer P Laux G Therapeutic drug monitoring of psychotropics: Report of a consensus conference Pharmacopsychiatry 1992, 25:271-272. 1494593
53. Baumann P Hiemke C Ulrich S Eckermann G Gaertner I Gerlach M et al. The AGNP-TDM expert group consensus guidelines: Therapeutic drug monitoring in psychiatry Pharmacopsychiatry 2004, 37:243-265. 10.1055/s-2004-832687 15551191
54. Hiemke C Hartter S Weigmann H Therapeutisches Drug Monitoring (TDM) Laboruntersuchungen in der psychiatrischen Routine Stuttgart: Thieme Gastpar M, Banger M 2000, 106-133.
55. Therapeutic Drug Monitoring Kinder- und Jugendpsychiatrie (in German) 2008 http://www.tdm-kjp.de
56. Gerlach M Hunnerkopf R Rothenhofer S Libal G Burger R Clement HW et al. Therapeutic drug monitoring of quetiapine in adolescents with psychotic disorders Pharmacopsychiatry 2007, 40:72-76. 10.1055/s-2007-972573 17447177
57. Gerlach M Rothenhofer S Mehler-Wex C Feggert JM Schulz E Wewetzer C et al. Therapeutisches Drug-Monitoring in de rKinder- und Jugendpsychiatrie -Grundlagen und praktische Empfehlungen Z Kinder Jugendpsychiatr Psychother 2006, 34:5-13. 10.1024/1422-4917.34.1.5 16485609
58. March JS Karayal O Crisman A CAPTN: The pediatric adverse event rating scale Proceedings of the 54th Annual Meeting of the American Academy of Child and Adolescent Psychiatry 2007
59. Nissen SE ADHD drugs and cardiovascular risk N Engl J Med 2006, 354:1445-1448. 10.1056/NEJMp068049 16549404
60. Health Canada Health Canada allows Adderall XR back on the Canadian market 2005 http://www.fda.gov/CDER/Drug/infopage/adderall/default.htm
61. Isojarvi I Jaatikainen TJ Pakarinen AJ Juntunen K Myllyla VV Polycystic ovaries and hyperandrogenism in woment taking valproate for epilepsy N Engl J Med 1993, 329:1383-1388. 10.1056/NEJM199311043291904 8413434
62. Swann AC Major system toxicities and side effects of anticonvulsants J Clin Psychiatry 2001, 62;16-21. 11469670
63. Scheffner D Konig S Rauterberg-Ruland I Kochen W Hofmann WJ Unkelbach St Fatal liver failure in 16 children with valproate therapy Epilepsia 1988, 29:530-542. 10.1111/j.1528-1157.1988.tb03757.x 3137017
64. Grauso-Eby NL Goldfarb O Feldman-Winter LB McAbee GN Acute pancreatitis in children from valproic acid: Case series and review Pediatric Neurology 2003, 28:145-148. 10.1016/S0887-8994(02)00517-9 12699868
65. Binek J Hany A Heer M Valproic-acid-induced pancreatitis. Case report and review of the literature J Clin Gastroenterol 1991, 13:690-693. 10.1097/00004836-199112000-00016 1761843
66. Mackay FJ Wilton LV Pearce GL Freemantle SN Mann RD Safety of long-term lamotrigine in epilepsy Epilepsia 1997 38 881 886 10.1111/ j.1528-1157.1997.tb01252.x 9579888
67. Garland EJ Facing the evidence: Antidepressant treatment in children and adolescents (Commentary) Can Med Assoc J 2004, 170:489-491. 10.1503/ cmaj.1040687
68. Wilens TE Biederman J Kwon A Chase R Greenberg L Mick E et al. A systematic chart review of the nature of psychiatric adverse events in children and adolescents treated with selective serotonin reuptake inhibitors J Child Adolesc Psychopharmacol 2003, 13:143-152. 10.1089/ 104454603322163862 12886909
69. Safer DJ A comparison of risperidone-induced weight gain across the age span J Clin Psychopharmacol 2004, 24:429-436. 10.1097/ 01.jcp.0000130558.86125.5b 15232335
70. Fleischhaker C Heiser P Hennighausen K Herpertz-Dahlmann B Holtkamp K Mehler-Wex C et al. Clinical drug monitoring in child and adolescent psychiatry: Side effects of atypical neuroleptics J Child Adolesc Psychopharmacol 2006, 16:308-316. 10.1089/cap.2006.16.308 16768638
71. Gracious BL Findling RL Seman C Youngstrom EA Demeter CA Calabrese JR Elevated thyrotropin in bipolar youths prescribed both lithium and divalproex sodium J Am Acad Child Adolesc Psychiatry 2004, 43:215-220. 10.1097/00004583-200402000-00018 14726729
72. FDA FDA Alert: Desmopressin Acetate 2007 http://www.fda.gov/cder/drug/ infopage/desmopressin/default.htm
73. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research The Belmont report-Ethical principles and guidelines for the protection of human subjects of research Federal Register 1979, 44(76);23192-23197.